Using notifications data to increase hepatitis C testing and treatment rates in Queensland.

Q3 Medicine
Morris Carpenter, Linda A Selvey, Stephen B Lambert, Robert Kemp
{"title":"Using notifications data to increase hepatitis C testing and treatment rates in Queensland.","authors":"Morris Carpenter, Linda A Selvey, Stephen B Lambert, Robert Kemp","doi":"10.33321/cdi.2023.47.62","DOIUrl":null,"url":null,"abstract":"<p><p>Australia's goal of eliminating hepatitis C by 2030 requires increases in uptake of and access to testing and treatment. As hepatitis C is a notifiable condition, health departments have access to information about people exposed to the hepatitis C virus (HCV), including the details of notifying clinicians who ordered their diagnostic pathology tests. Hepatitis C RNA testing confirms active infection that requires treatment, whereas a positive antibody test result only indicates prior exposure to the virus. We undertook a pilot project in Queensland to follow up hepatitis C notifications with clinicians, aiming to increase HCV-RNA testing and treatment uptake. For all individuals with a first-time hepatitis C notification in Queensland between 3 November 2020 and 28 May 2021, we sought information regarding hepatitis C RNA testing from laboratories, excluding those cases diagnosed in prisons. Cases who did not have RNA testing identified as part of or after their initial diagnostic tests were followed up via their notifying clinician. Interviews with selected clinicians were undertaken to improve our understanding of the follow-up process. There were 769 new hepatitis C notifications during our study period: 244 had no subsequent RNA test identified and were followed up for this study. Of these, 134 cases were lost to follow-up; 26 were already being effectively case managed; 22 reported previous treatment and no further risk; and 62 were eligible for HCV-RNA testing. Twenty-six cases subsequently started hepatitis C treatment. Thirty-four percent of notifications that required follow-up resulted from testing initially requested in hospital settings. Following up hepatitis C notifications can result in increased treatment rates; however, the process was resource-intensive and often failed to result in further contact between clinicians and patients. Our findings also highlight the importance of supporting better continuity of care between hospitals and community settings.</p>","PeriodicalId":36867,"journal":{"name":"Communicable diseases intelligence (2018)","volume":"47 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communicable diseases intelligence (2018)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33321/cdi.2023.47.62","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Australia's goal of eliminating hepatitis C by 2030 requires increases in uptake of and access to testing and treatment. As hepatitis C is a notifiable condition, health departments have access to information about people exposed to the hepatitis C virus (HCV), including the details of notifying clinicians who ordered their diagnostic pathology tests. Hepatitis C RNA testing confirms active infection that requires treatment, whereas a positive antibody test result only indicates prior exposure to the virus. We undertook a pilot project in Queensland to follow up hepatitis C notifications with clinicians, aiming to increase HCV-RNA testing and treatment uptake. For all individuals with a first-time hepatitis C notification in Queensland between 3 November 2020 and 28 May 2021, we sought information regarding hepatitis C RNA testing from laboratories, excluding those cases diagnosed in prisons. Cases who did not have RNA testing identified as part of or after their initial diagnostic tests were followed up via their notifying clinician. Interviews with selected clinicians were undertaken to improve our understanding of the follow-up process. There were 769 new hepatitis C notifications during our study period: 244 had no subsequent RNA test identified and were followed up for this study. Of these, 134 cases were lost to follow-up; 26 were already being effectively case managed; 22 reported previous treatment and no further risk; and 62 were eligible for HCV-RNA testing. Twenty-six cases subsequently started hepatitis C treatment. Thirty-four percent of notifications that required follow-up resulted from testing initially requested in hospital settings. Following up hepatitis C notifications can result in increased treatment rates; however, the process was resource-intensive and often failed to result in further contact between clinicians and patients. Our findings also highlight the importance of supporting better continuity of care between hospitals and community settings.

利用通知数据提高昆士兰丙型肝炎检测和治疗率。
澳大利亚到2030年消除丙型肝炎的目标要求提高检测和治疗的接受率和可及性。由于丙型肝炎是一种应报告的疾病,卫生部门可以获得有关接触丙型肝炎病毒(HCV)的人的信息,包括通知要求进行诊断性病理检查的临床医生的详细信息。丙型肝炎病毒核糖核酸检测证实了需要治疗的活动性感染,而抗体检测结果呈阳性仅表明先前接触过该病毒。我们在昆士兰开展了一个试点项目,与临床医生一起跟进丙型肝炎通知,旨在提高HCV-RNA检测和治疗的接受率。对于2020年11月3日至2021年5月28日期间在昆士兰首次收到丙型肝炎通知的所有人,我们从实验室寻求有关丙型肝炎RNA检测的信息,不包括在监狱中诊断的病例。在最初的诊断测试中或之后没有进行RNA测试的病例通过通知临床医生进行随访。对选定的临床医生进行了访谈,以提高我们对随访过程的理解。在我们的研究期间,共有769例新的丙型肝炎通知:244例没有随后的RNA检测,并在本研究中进行了随访。其中134例失访;26人已经得到有效的案件管理;22例报告既往治疗,无进一步风险;62人符合HCV-RNA检测条件。26例患者随后开始接受丙型肝炎治疗。34%需要随访的通知来自最初在医院要求的检测。对丙型肝炎的通知进行跟进可以提高治疗率;然而,这一过程是资源密集型的,往往无法导致临床医生和患者之间的进一步接触。我们的研究结果还强调了支持医院和社区环境之间更好的连续性护理的重要性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.90
自引率
0.00%
发文量
72
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信